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Background/aim: Alzheimer disease, a common proteopathy of advanced age, is characterized by cortical atrophy, neuron degeneration,
neuronal loss, and accumulation of extracellular amyloid β plaques. We aimed to investigate serum vitamin B12 and folic acid levels
in Alzheimer disease and other dementia patients, as a potential screening test to detect presymptomatic Alzheimer disease in Turkish
patients.
Materials and methods: We evaluated folic acid and vitamin B12 levels in Alzheimer disease patients as well as in other dementia and
geriatric patients from Ankara, Dokuz Eylül, and Çukurova university hospitals; 290 female and male geriatric subjects were enrolled.
Vitamin B12 and folic acid levels were measured using Roche E170 and Beckman Coulter DXI 800 immunoassays (chemiluminescence)
according to the manufacturers’ guideline in all centers.
Results: We evaluated the results of folic acid and vitamin B12 in Alzheimer disease, other dementias and geriatric patients. No
significant difference between the groups regarding the routine control of biochemical parameters was observed.
Conclusion: Currently, serum folic and vitamin B12 levels are not diagnostically reliable tests for screening presymptomatic Alzheimer
disease. However, the results may statistically be significant if we increase the sample size.
Key words: Alzheimer disease, vitamin B12, folic acid

1. Introduction
Almost a century ago, Alzheimer disease was first described
by German psychiatrist and neuropathologist Alois
Alzheimer and named after him (1). Alzheimer disease
is the most common form of dementia of the human
central nervous system. This protein misfolding disease
(proteopathy) accounts for an estimated 60%–80% of
cases of dementia (2,3). Alzheimer disease is a very severe
public-health problem, especially in view of increased
life span. In fact, approximately 50% of people over age
85 suffer from it. The global prevalence of dementia has
been estimated to double every 20 years and consequently,
by 2040, as many as 24 million new diagnoses are on the
horizon, which is an enormously challenging number (4).
Following in the footsteps of global trends in increasing
* Correspondence: nulusu@ku.edu.tr

human longevity, the elderly population ratio projects an
incremental pattern in Turkey as well. It is estimated that
the average life expectancy is 71.8 for men and 76.8 for
women as of 2010 (5).
Alzheimer disease is multifactorial brain impairment
and the causes of the degenerative brain function remain
unknown (6). Through the interplay of underlying
genetics and biochemical derangements, in addition
to environmental factors, Alzheimer disease has some
features that distinguish this disease from the other
neurodegenerative disease types such as neuronal loss,
accumulation of extracellular (amyloid β containing)
plaques, and accumulation of intracellular (tau)
neurofibrillary tangles, which are the dominant traits of
this disease. Beside these features, cortical atrophy and
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neuron degeneration are also commonly seen as the disease
progresses and dementia sets in. In the very etiology of
tangles and senile plaques accumulation, oxidative stress
has a triggering effect in emergence of disease-related
pathologies (7–10). Amyloid β (Aβ) plaques and tangles
are characteristic major markers of Alzheimer disease and,
in addition to these properties, tau phosphorylation is
one of the most important fundamental factors in disease
progression (11,12). In fact, it was discovered that female
patients with psychotic Alzheimer disease, but not males,
have significantly higher levels of phosphorylated tau in the
frontal cortex. Male sex, but not female, is associated with
the presence of α-synuclein pathology, which supports a
sex dissociation of pathology in Alzheimer patients with
psychotic disease (13).
Various neurochemical as well as serum biomarkers are
proposed in Alzheimer disease as indicators to assess the
risk or presence of the disease. For this end, biochemical
clinical laboratory blood tests may have critical and
potential roles in some aspects such as identifying comorbidity and screening complications of the patients to
provide appropriate care. These tests may also be important
for evaluation of the other potential risk factors such as
identifying and discovering associated correlations (14).
In fact, in clinical medicine, biomarkers provide reliable
and objective measures to assess disease progression as
well as being indispensable for early detection.
For a better and coherent understanding of complex
disease pathologies in Alzheimer disease, which may in
turn be translated into patient care, instead of fixation on
an isolated system, a multifactorial, holistic approach that
includes the exploration of enzyme deficiencies is essential
(12,14). In fact, research investigating the analysis of Aβ
(1-42), total tau, and phospho-tau-181 in cerebrospinal
fluid allows a reliable, sensitive, and specific diagnosis of
Alzheimer disease but not of other forms of dementia (14).
Aging begins at a molecular level. In our previous
study, we concluded that the enzymes isolated from
young animals (15) and old animals present variations in
kinetic behavior as a result of the natural aging process
(16). Studies in recent years have shown the importance
of progression of brain aging is influenced by a complex
interaction of genetic and environmental factors (17). It is
also established that brain activities, correlated with brain
gray matter structures, undergo changes through aging.
It is also known that there is an important reduction in
the volume and size of the cortex (18,19). Once again, the
potential effect of nutrition has become a trending subject
in scientific and public interest in reversing the detrimental
cognitive/motor decline. There are debates that foods
that contain specific vitamins, trace minerals, and lipids
can affect the risk of cognitive decline and dementia,
especially in frail elderly people at risk of deficiencies (20).
Furthermore, adequate dietary nutrition intake thorough
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a healthy and balanced diet has an undisputed role in
healthy aging as its essentiality has been confirmed by
various researchers (21,22).
Vitamin B12 is a complex organometallic cofactor
that has crucial roles associated with 3 subfamilies of
enzymes: the adenosylcobalamin-dependent isomerases,
the methylcobalamin-dependent methyltransferases, and
the dehalogenases (23). Folic acid, on the other hand, is
essential for numerous bodily functions. Folic acid is not
biologically active on its own; its biological importance is
due to tetrahydrofolate and other folic acid derivatives. The
human body needs folic acid in DNA and RNA synthesis,
as well as in DNA methylation and the reactions that
require single, activated carbon transfer. The metabolisms
of folic acid and vitamin B12 intersect during the transfer
of the methyl group from 5-methyltetrahydrofolate to
homocysteine catalyzed by B12-dependent methionine
synthase. Regeneration of tetrahydrofolate via this
reaction makes it available for synthesis of nucleotide
precursors (24). Due to its indispensable roles in normal
human metabolism, folic acid fortification of breakfast
cereals, a popular consumer product in Western diet,
was introduced in many countries to prevent neural tube
defect occurrence.
Folate and/or vitamin B12 deficiency may have
additive effects in many diseases including various types
of dementia (25).
In order to investigate a potential correlation between
B12 and folic acid deficiency and Alzheimer disease, we
analyzed the serum B12 and folic acid results of Alzheimer
disease patients and geriatric patients from various cities in
Turkey. We selected these cities from different geographic
regions of Turkey; Ankara is in the Central Anatolia
region, İzmir is in the Aegean region, and Adana is in the
Mediterranean region. These 3 geographic regions are
quite distinct from one other in terms of their populations’
diverging dietary habits and lifestyles, and even climate
conditions.
Through this study, we aim to determine a simple
and cost-effective method that may be beneficial in early
diagnosis by recognizing the warning signs of Alzheimer
disease and screening to identify individuals who have
disease but do not yet have symptoms.
2. Materials and methods
Subject enrolment lasted for 1 year (2013–2014), at
Ankara, Çukurova, Dokuz Eylül university hospitals’
neurology clinics. Patients’ medical records for serum
vitamin B12 and folic acid were examined retrospectively
for a correlation between serum levels and cognitive
decline documented with a clinical diagnosis of dementia.
Patients with clinically documented malignancies, drug
and/or alcohol abuse, and ongoing vitamin replacement
therapies were excluded from the study.
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2.1. Biochemical measurements and sampling
In all 3 centers, biochemical measurements were made
according to these rules: all patients’ blood samples were
collected after a 10–12-h fasting period. Venous blood
samples, which were drawn between 0900 and 1100, were
stored at 4 °C. Vitamin B12 and folic acid levels were
measured using Roche E170 and Beckman Coulter DXI
800 immunoassays (chemiluminescence) according to
manufacturers’ guidelines.
2.2. Statistical analysis
We evaluated our results as mean ± standard deviation
(SD). The Kolmogorov–Smirnov test was used to check
correlations between variables and the normal distribution
and homogeneity among subgroups was analyzed with the
Levine test. In subgroup comparisons, as the parametric
test assumptions were met, one way ANOVA was used.
Since there was a variation in the average age among
subgroups in 2-group comparisons, Tamhane’s post hoc
test was adopted. Finally, in discerning the sex variations,
we chose the chi-square test.
P-values < 0.05 were considered statistically significant for
all analyses.
3. Results
In this retrospective study 290 female and male geriatric
subjects were enrolled. We aimed to identify Alzheimer
disease during preclinical, asymptomatic phases before
the onset of cognitive decline. Patients’ data were collected
from 3 different centers and were evaluated for serum

folic acid and B12 vitamin retrospectively. From Adana
center (Çukurova University Hospital, Neurology Clinic),
94 subjects were recruited, of which 49 were female and
45 male. Patients with a previous history of vitamin
replacement therapy were excluded.
Subjects were further divided and assigned to 3
subgroups according to their symptoms (Figures 1 and
2). While the first subgroup included subjects with
mixed-type Alzheimer disease (no: 38) (vascular type
+ Alzheimer disease), the second subgroup included
subjects with Alzheimer disease (n: 37). Finally the third
subgroup included subjects suffering from vascular-type
dementia (n: 19). In the first subgroup, the average age
of the subjects was 83.26 ± 6.38 (75–104), and vitamin
B12 (Figure 1) and folate levels (Figure 2) were 222.79 ±
117.67 (41–506) and 4.58 ± 2.88 (1–10), respectively. In
the second subgroup, the average age of the subjects was
76.57 ± 7.6 (55–89), and while the serum vitamin B12
levels were 244.08 ± 105.52 (75–524), serum folate levels
were 6.15 ± 4.73 (1–26). Finally, in the third subgroup, the
average age among the subjects was 65.58 ± 13.97 (40–91),
and serum vitamin B12 and folate levels were 184.58 ±
96.46 (58–443) and 4.42 ± 1.80 (1–8), respectively. In the
third subgroup, although not statistically significant, both
vitamin B12 and folic acid levels were lower compared to
the other groups (Figures 1 and 2).
When the 94 subjects from the Adana center were
divided into 2 groups according to their age, as above 65
and below 65, in the 82 subjects 65 or older, the average

Figure l. Results of serum vitamin B12 in patients with Alzheimer disease and other
dementias from the Mediterranean region, Adana, Çukurova University Hospital.
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Figure 2. Results of serum folic acid in patients with Alzheimer disease and other
dementias from the Mediterranean region, Adana, Çukurova University Hospital.

vitamin B12 level was 222.83 ± 103.53 and the average
folate level was 4.58 ± 2.50. In the 12 subjects younger
than 65, the average vitamin B12 level was 223.54 ± 111.51
and the average folate level was 5.25 ± 3.78. No meaningful
variation in vitamin B12 or folate levels was observed
between the groups (Figures 1 and 2).
In the İzmir center (Dokuz Eylül University Hospital,
Neurology Clinic), 119 subjects were recruited, of which
73 were female and 46 male. The subjects were further
divided and assigned to 4 subgroups according to their
clinically observable symptoms. While the first subgroup
included subjects with Alzheimer disease (n: 37), the
second subgroup included subjects with frontotemporal
dementia (n: 7). The third subgroup included subjects
suffering from early-onset dementia (n: 22) and the fourth
subgroup consisted of normal geriatric subjects.
In the first subgroup, the average age of the subjects
was 76.54 ± 7.96 (66–95), and vitamin B12 and folate levels
were 469.59 ± 237.08 (155–1000) and 8.04 ± 5.44 (1.8–25),
respectively. In the second subgroup, the average age of the
subjects was 78.42 ± 5.56 (69–84), and while the serum
vitamin B12 levels were 601.57 ± 388.89 (167–1244),
serum folate levels were 5.36 ± 1.63 (3.2–7.5). In the third
subgroup, the average age among the subjects was 60.36 ±
3.37 (54–65), and serum vitamin B12 and folate levels were
561.86 ± 258.20 (214–1307) and 6.37 ± 1.91 (2.4–10.7),
respectively. Finally, in the normal geriatric subjects, the
average age was 78.18 ± 7.09 (66–93) and while vitamin
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B12 levels were 474.35 ± 320.59 (123–2000), folate levels
were 6.85 ± 3.61 (2.4–25) (Figures 3 and 4).
Although there was a statistically significant difference
(P < 0.001) between the groups in terms of average age, no
statistically significant difference was observed for vitamin
B12 (0.29) or folate (P: 0.50).
Even though there was no statistically significant
difference in the second and the third subgroups, while
folic acid levels were noted as lower, vitamin B12 levels
were found to be higher, compared to the other groups
(Figure 3).
From the Ankara center (Ankara University
Hospital, Geriatric Clinic), 122 subjects were recruited
(61 Alzheimer disease patients and 61 normal geriatric
patients). Patients with a previous history of vitamin
replacement therapy were excluded. The 122 subjects from
the Ankara center were divided into 2 subgroups: while the
first subgroup included patients with Alzheimer disease,
normal geriatric subjects were assigned to the second
subgroup (Figures 5 and 6). Serum folic acid values of
4.6–18.7 ng/mL and serum vitamin B12 values of 191–663
pg/mL are considered to be in the normal reference range
and according to these reference values, in our study, we
identified 5 Alzheimer patients with below-normal folic
acid levels.
However, in the second subgroup with normal geriatric
subjects, only 3 subjects had normal reference range folic
acid levels. Only 3 subjects with Alzheimer disease had
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Figure 3. Results of serum vitamin B12 in patients with Alzheimer disease and other
dementias from the Aegean region, İzmir, Dokuz Eylül University Hospital.

Figure 4. Results of serum folic acid in patients with Alzheimer disease and other
dementias from the Aegean region, İzmir city, Dokuz Eylül University Hospital.

below-normal vitamin B12 levels and, interestingly, 20
subjects with higher than normal vitamin B12 levels were
identified. In addition to this unexpected result, vitamin
B12 levels were completely in the reference range in all of
the geriatric patients from the second subgroup.

4. Discussion
It is accepted that the major cause of Alzheimer disease
is old age. However, it is a multifactorial irreversible
neurodegenerative disease among individuals over the
age of 85 and its pathophysiologic mechanism is not
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Figure 5. Results of serum vitamin B12 in normal geriatric patients from the Central
Anatolia region, Ankara, Ankara University Hospital.
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Figure 6. Results of serum folic acid in normal geriatric patients from the Central
Anatolia region, Ankara, Ankara University Hospital.

fully understood (26). In a previous study, researchers
tried to address the question of whether it is possible to
prevent atrophy of key brain regions related to cognitive
decline and Alzheimer disease. One approach is to modify
nongenetic risk factors, for instance by lowering elevated
plasma homocysteine levels using vitamin B derivatives. In
an initial, randomized controlled study in elderly subjects
with increased dementia risk (mild cognitive impairment
according to 2004 Petersen criteria), researchers showed
that high-dose B-vitamin treatment (folic acid 0.8 mg,
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vitamin B6 20 mg, vitamin B12 0.5 mg) slowed shrinkage
of the whole brain volume over 2 years. In fact, it was
demonstrated that B-vitamin supplementation can indeed
slow the atrophy of specific brain regions that are key
components of the Alzheimer disease process and are
associated with cognitive decline (27).
Alzheimer disease affects patients in several ways
and we have identified the Alzheimer disease patients
according to the general symptoms such as memory loss
that interferes with the quality of daily life, for example
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confusion with time or place and especially in problems
with finding the correct expression in both oral and
written communication. Misplacing things and losing the
ability to sustain vital daily activities are other common
traits of this neurodegenerative disease. Accordingly,
personality changes are widely observed that affect the
patients’ professional and social lives.
Progression of the disease shows variation in Alzheimer
patients. While in some patients emergence of symptoms
presents a gradual pattern with decline in cognitive and
motor abilities, in others it may present a more rapid and
severe onset. Unaffected family members could sometimes
fall short in recognizing the failing brain functions and the
patients could feel isolated.
Metabolism of homocysteine is innately related
to metabolism of vitamin B12 and folic acid, and the
deficiencies of these 2 crucial vitamin products could
result in high homocysteine levels, which in turn increase
the susceptibility for cerebrovascular diseases (22,28).
Nonetheless, due to insufficient subject numbers enrolled
in the study, higher than normal vitamin B12 level results
and, more importantly, homocysteine levels were not
included in the scope of this study, and so it is not possible
to derive direct conclusions.
Intake of sufficient vitamins and other nutritional factors
is crucial in healthy aging. In fact, aging as a molecular
process begins with the alterations of biochemical processes
that synthesize biologically important macromolecules. In
addition to this subtle yet highly significant remodeling,
excessive production of reactive oxygen species (ROS)
may lead to cellular injury through base breaks in DNA,
and nonspecific modifications and disruption of proteins,
phospholipids, and nucleic acids. In fact, accumulations of
these detrimental effects are considered to be the prime
suspect behind many clinically challenging diseases,
including Alzheimer disease.
Changes in kinetic behavior of enzymes as well as the
clinically symptomatic enzyme deficiencies have additive
effects in molecular aging and are highly relevant in
pathologies. As the trends in clinical medicine shift to
multifactorial evaluations in discerning human diseases,

many are now correlated with the altered enzymatic
activities. In this study, we analyzed vitamin B12 and folic
acid levels in dementia patients including Alzheimer and
normal geriatric patients.
5. Conclusion
Alzheimer disease is a complex, multifaceted disease that
has genetic, molecular, cellular, enzymatic, nutritional,
organ, and system levels of implications. With the
improvements in modern medical sciences, average
human life has increased exponentially. However, it is now
an established fact that many diseases, including but not
limited to cancer and neurodegenerative ones, in fact have
a high prevalence among the elderly population. Many of
the random and deleterious biochemical alterations that
are prevalent in advanced age could induce progressive
damage at cellular level and these driving factors make
leeway for Alzheimer disease and other dementias.
We are trying to find a biomarker in the patients with
Alzheimer disease that is to be used as an indicator of a
precise presymptomatic biological state or condition
before the onset of dementia as a screening test and for
the differential diagnosis of neurodegenerative diseases.
Our secondary aim is to learn the differences between
Alzheimer disease and geriatric patient populations’
laboratory results for vitamin B12 and folic acid.
In our opinion, although fast and cost-effective,
biochemical routine works such as blood biomarkers,
for the time being, are not reliable for identification
of presymptomatic Alzheimer disease. However,
ultrasensitive analytical methods have potency to provide
physicians with an opinion about the status of the patient.
With our current understanding, Alzheimer disease has
no cure and therefore is still a challenging disease with
both sociological as well as clinical implications and we are
confident that biomarker discovery as a rapidly expanding
field of research will soon come up with a solution for
screening patients at high risk for neurodegenerative
diseases even before they become symptomatic or severely
deficient in both cognitive as well as motor functions.
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